Human myeloid leukemia cell lines are induced to terminal differentiation into monocyte lineage by 1,25-dihydroxyvitamin D 3 (1,25D 3 ) or its analogs (deltanoids). However, translation of these findings to the clinic is limited by calcemic effects of deltanoids. Strategies to overcome this problem include combination of deltanoids with other compounds to induce differentiation at lower, noncalcemic, deltanoid concentrations. We previously showed that either carnosic acid, an antioxidant, or SB202190, a p38 MAPK inhibitor, increase the potency of 1,25D 3 in the HL60 cell line. Here, we report that simultaneous addition of both these agents further increases differentiation potency of deltanoids in this cell line and in freshly obtained leukemic cells ex vivo. Activity of MAPK pathways showed that increased differentiation was associated with enhanced activity of JNK pathway in all responding cell subtypes. Our studies suggest that patients with CML or AML subtypes M2 and M4, but not M1, M3 or M4eo, are particularly suitable for this combination therapy. We conclude that the established cell line HL60 presents a good model for some, but not all, subtypes of myeloid leukemia, and that the JNK pathway plays an important role in monocytic differentiation of human leukemic cells ex vivo, as well as in vitro.
Introduction
Acute myeloid leukemias (AML) are characterized by a block in differentiation of predominantly granulocytic or monocytic progenitor cells, which leads to accumulation of immature myeloid cells in bone marrow and peripheral blood. Current attempts to reduce the numbers of these immature, nonfunctioning cells primarily utilize chemotherapy, and to a lesser extent, differentiation therapy. Chemotherapy, which although cytotoxic to malignant clones, is also cytodestructive to normal cells, and some leukemia cells develop resistance to chemotherapy and are therefore difficult to eradicate. Differentiation therapy, with the goal of arresting the growth of malignant cells by inducing normalization of cellular phenotype without damage to normal tissues, provides an alternative strategy for the treatment of several types of neoplastic diseases. A notable example of the success of this approach is provided by the use of the vitamin A derivative all-trans retinoic acid (ATRA), which has been particularly effective in the treatment of acute promyelocytic leukemia by inducing the neoplastic promyelocytes to differentiate into neutrophil-like cells. 1, 2 Derivatives of vitamin D, including 1,25-dihydroxyvitamin D 3 (1,25D 3 ), the physiologically active form of vitamin D 3 , induce differentiation of leukemic myeloid cells along the monocyte/macrophage lineage and inhibit their proliferation in vitro and ex vivo. [3] [4] [5] In vivo, the survival of mice challenged with syngeneic leukemic cells is enhanced by treatment with 1,25D 3 . 6, 7 Koeffler's group, 8 and later Kelsey et al, 9 reported that oral administration of 1,25D 3 to patients with myelodysplasia produced a partial but sustained hematological response, in terms of increases in neutrophil and platelet counts, in approximately half of the treated patients. However, hypercalcemia occurred in some patients before concentrations necessary for antileukemic activity could be achieved. Animal studies have also highlighted that the major limitation for the clinical use of the hormone is its potent calcemic activity, which results in hypercalcemia, tissue calcifications and hypercalciuria. 10 Attempts to overcome the hypercalcemia problem focus on the synthesis of analogs of 1,25D 3 ('deltanoids'), based on studies which suggest that the differentiation-inducing capacity and the hypercalcemic effects may be separable by modifying the structure of the 1,25D 3 .
11 Yet another strategy to obviate this obstacle is to combine relatively low doses of deltanoids with the administration of another agent, such as an antioxidant, which augments the differentiation-inducing action of deltanoids, but does not enhance the levels of circulating calcium. For instance, it was shown that ascorbic acid and vitamin E enhance 1,25D 3 -induced monocytic differentiation of HL60 cells, 12, 13 and that the antioxidants carnosic acid (CA), curcumin, ebselen and silibinin potentiate monocytic differentiation induced by low concentrations of 1,25D 3 .
14 Further, the inhibition of the signaling kinase p38 MAPK by its specific inhibitors SB203580 (SB203) or SB202190 (SB202) markedly accelerates monocytic differentiation of HL60 cells induced by low concentrations 1,25D 3 . 15 In this study, we first used an established human myeloid leukemia cell line HL60 to determine the most effective combinations of deltanoids with the antioxidant CA and the p38 MAPK inhibitor SB202. We then translated the findings from this cell line to primary human leukemic cells cultured ex vivo by investigating which subtypes of leukemia respond to these combinations of agents, and found that data obtained using the HL60 cell line and several subtypes of myeloid leukemia cells ex vivo are comparable. We also determined that the JNK MAP kinase pathway has an important role in monocytic differentiation induced by these combinations both in vitro and ex vivo. 
Materials and methods

Chemicals and antibodies
Cell culture
HL60-G cells, a subclone of human promyeloblastic leukemia HL60 cells, 16 was grown as previously described.
14 Each experiment with cell lines was repeated at least three times.
Patients for ex vivo studies
The study population comprised seven male subjects and five female subjects with a median age of 60 years. These were the consecutive patients who presented to the UMDNJ-University Hospital between July 2003 and January 2005 with some form of myeloid leukemia and gave informed consent for this study. All of the AML and CML leukemias were de novo leukemia. There were two M1, one M2, one M3 (APL), three M4 (including one M4eo) subtypes, two CML, two MDS, and one CMML patients. In two patients an abnormal karyotype was detected ( Table 1) .
Isolation of the mononuclear cells from patients' peripheral blood
The specimens of peripheral blood from patients with myeloid leukemia were obtained following the patient's informed consent according to the Institutional IRB protocol. Cells were separated by ficoll gradient centrifugation, and cultured with deltanoids, CA, or SB202 as described, for periods of time ranging from 48 to 96 h in RPMI plus 10% bovine calf serum.
Determination of markers of differentiation
Monocytic differentiation was monitored by the expression of differentiation markers CD14 and CD11b, determined by flow cytometry, and cytochemical determination of the cytoplasmic enzyme monocytic specific esterase (MSE) activity, as described previously. 14 
Western blotting
This procedure was carried out as previously described. 14 
Results and discussion
Addition of the p38 MAPK inhibitor SB202, an antiinflammatory agent, and CA, an antioxidant, to vitamin D analogs increases monocytic differentiation of AML cells HL60 in established culture in vitro Our laboratory previously reported that inhibition of the signaling protein p38 MAP kinase by its specific inhibitors SB203 or SB202, or addition of the plant antioxidant CA, markedly accelerates monocytic differentiation of HL60 cells induced by 1 nM 1,25D 3 .
14,15 Therefore, we set out to investigate which combinations of these compounds induce differentiation most effectively, at first using a freely available AML cell line HL60, in order to translate the findings to freshly obtained leukemia blood samples, which provide limited numbers of cells. We also utilized in this study deltanoids 1,25D 3, Ro25-4020, Ro26-3884, PRI-1906, PRI-2191 which have been shown to be less calcemic to animals than 1,25D 3 , 17 and thus have potential for clinical use in the treatment of human malignancies.
As shown in Figure 1 , monocytic phenotype characterized by the expression of the CD14 surface marker, the cytoplasmic enzyme MSE, and CD11b, a general myeloid differentiation marker, was clearly evident in HL60 cells treated with these deltanoids (columns 5, 9, 13, 17, 21), but was minimal or absent in cells treated with each CA or SB202 alone (columns 2 or 3). The JNK MAP kinase pathway is upregulated in HL60 cell in parallel with differentiation by CA and/or SB202 and deltanoids
Our laboratory has shown that MAP kinase pathways participate in 1,25D 3 -induced differentiation of HL60 cells. [18] [19] [20] To study the mechanisms of the potentiating effect of CA and SB202, we first examined activation by these compounds of the three MAP kinase cascades, the JNK, ERK, and p38 pathways in this cell line.
The phosphorylation of the p54 JNK2 isoform of JNK, indicative of its activation, increased following the treatment of the cells with 1,25D 3 and deltanoids 2191 and 4020 (Figure 2a) . A small increase was also noted in the level of phosphorylation of p46 JNK1, and these increases became somewhat more prominent when the deltanoids were combined with CA or SB, and even more prominent when deltanoid 4020 was combined with both CA and SB. Phosphorylation of transcription factors c-jun and ATF-2, the downstream targets of JNKs, was also increased, most markedly following treatment Combinations of carnosic acid, SB202, and 1,25D 3 or its analogs are potent inducers of monocytic differentiation in HL60 cells. HL60 cells were treated with the compounds as indicated for 72 h, and differentiation markers were determined by flow cytometry (CD11b and CD14) and cytochemistry (MSE). Note that differentiation was increased in HL60 cells treated with deltanoids, or combinations of deltanoids and CA/SB202, or combinations of deltanoids, CA, and SB202 (DCS). DCS combinations were the most potent differentiation inducers. The experimental groups marked (DCS, triple combination) with an asterisk were significantly increased compared to groups treated with combinations of the same deltanoid with either CA or SB202 (DC or DS) ( n Po0.05). Effect of CA, SB202, deltanoids, or their combinations on activation of MAP kinase pathways in HL60 cells. HL60 cells were treated with the indicated compounds for 72 h, and proteins in whole cell lysates were subjected to 10% SDS-PAGE gel electrophoresis, transferred to nitrocellulose membranes, and incubated with the indicated antibodies, then reprobed for Crk-L protein as a loading control.
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Q Wang et al with combinations DCS. Importantly, the upregulation of the JNK pathway taken as a whole appeared to correlate the expression of the differentiation markers, and was most apparent with deltanoid 4020.
Phosphorylation of MEK, ERK and p38, was increased following the treatment by SB202 alone or in combination with other compounds, but this did not correlate induction of differentiation (Figure 2b and c) . However, phosphorylation of Response of primary myeloid leukemia cells to deltanoids (D) and combination of deltanoids with carnosic acid and SB202 (DCS). Peripheral white blood mononuclear cells isolated from myeloid leukemia and MDS patients were treated as indicated for 72 h, and differentiation markers were determined by differentiation markers CD14 (a), CD11b (b), and MSE (c). The column graphs show the increase/decrease in marker positive cells (%) relative to the untreated control (CON) in each case. The capital letter below each groups of column denotes the patients listed in Table 1 .
Induction of differentiation of myeloid leukemia Q Wang et al p90RSK, which is believed to be a downstream target of ERK showed a different pattern from that of ERK activation. Thus, it is possible that in the leukemia cell system p90RSK is phosphorylated by kinases other than ERK.
While the increased phosphorylation of p38 may appear paradoxical in these experiments, SB202 inhibits p38 activity, but not its phosphorylation. The observed increase in phosphorylation of p38, and of JNK, can be explained by loss of feedback inhibition of ras by a downstream targets of p38, MAPKAPK-2 or PRAK. 15, 21 We have confirmed that phosphorylation of MAP-KAPK-2 was not increased following exposure to SB202 (Figure 2c ).
Induction of differentiation of CML and AML cells treated ex vivo with deltanoids combined with CA and SB202
We used the deltanoids and the potentiators of differentiation found effective in experiments with HL60 cells described above, to induce differentiation of primary leukemia cells obtained directly from the peripheral blood of myeloid leukemia patients. Combination of CA and SB202 potentiated monocytic differentiation induced by deltanoids, as reflected by CD14, CD11b, and MSE (Figure 3) . Although the responses were variable, in general the induction of differentiation was seen following addition of a deltanoid, and was increased by the addition of SB202 and CA (Figure 3 ). Of note, the best responders were samples from patients with CML/CMML and AML M4 and to a lesser extent M2. The available samples of AML M1, M3 (APL), or MDS, responded minimally or not at all. Interestingly, the variant AML M4 with eosinophilic differentiation (sample H) responded to deltanoids modestly well, but addition of SB202 and CA inhibited the deltanoid effect (Figure 3) . We also noted that when the basal level of monocytic cells in the ex vivo sample was low, the induction by DSC combinations was less marked (data not shown).
Activation of JNK pathway, but not of ERK or p38 pathway, correlates with monocytic differentiation induced by DCS combinations in the ex vivo blood samples of myeloid leukemia
As described above, we observed that JNK MAP kinase pathway was upregulated by combinations of CA and/or SB202 and deltanoids in the established AML cell line HL60. We, therefore, examined the activation of the MAP kinase pathways in AML and CML cells responding ex vivo to the combination differentiation regimen (DCS). We found that the activity of the JNK pathway, as indicated by phosphorylation of JNK, c-jun and to a lesser extent ATF-2 was augmented by this combination (lanes 6, 8, 10, 12 in Figure 4a ). However, activation of MEK and ERK by this combination did not correlate with the differentiation, but was more related to the exposure of the cells to SB202, which increased phosphorylation of components of all three MAPK pathways studied here (Figure 4b) . Also, while the phosphorylation of p38MAPK was increased by treatment with SB202 or SB202 combined with the other compounds, its downstream target MAPKAPK-2 was not increased as much as p38MAPK, if any, indicating a partial inhibition of the p38MAPK Effect of CA, SB202, 1,25D 3 or its analogs, or their combinations, on MAP kinase pathways. Peripheral white blood cells isolated from an AML (sample E-M2) patients were treated for 72 h as indicated. Immunoblotting was performed as described in the legend to Figure 2 activity by SB202 (Figure 4c) . Thus, in the cases that we obtained significant numbers of cells to perform Western analysis, principally M2 and M4 AML, the MAPK upregulation pattern was essentially similar to the patterns obtained using established myeloid cell line HL60 (Figure 2 ). However, in contrast to HL60 cells, phosphorylation of JNK1 usually exceeds phosphorylation of JNK2 in ex vivo cells (Figure 4a and data not shown) .
In summary, we developed, using an established human leukemia HL60 cell line, a potent combination of monocytic differentiation inducers consisting of low calcemic deltanoids supplemented with CA and SB202. We then tested these combinations using a cohort of 12 consecutive primary human leukemic cells obtained from peripheral blood of patients and cultured ex vivo. We found that cells from AML FAB subtype M4, and to a lessor extent M2, responded to the combinations of deltanoids and these agents better than the other subtypes of AML. Also responsive were cells obtained from patients with CML and CMML, but M4eo, MDS, and APL were minimally responsive, if at all. We observed that the responses obtained from the cell line HL60 was comparable to data obtained from M2 and M4 primary leukemic cells.
We also initiated an investigation of the underlying mechanisms of potentiation of differentiation of these leukemia cells in vitro and ex vivo, with primary focus on the MAP kinase pathways. We found that in the HL60 established line and primary AML M2 and M4 FAB subtypes, JNK kinase pathway was upregulated by the combinations of CA, SB202, and deltanoids (DCS). This combination was more effective in upregulation of the JNK pathway than the individual differentiation inducers or pairs of inducers. This was reflected by phosphorylation and activation of JNK, c-jun, and ATF-2, though there were some differences in the various cell subtypes. The phosphorylation of components of the ERK and p38 MAP kinase pathways did not parallel differentiation, and appeared to be direct effects of SB202.
At present, AML continues to be characterized by a 5 year survival rate of less than 50% overall; thus, adjuncts to conventional chemotherapy which may improve outcome clearly merit investigation, particularly for patients with subtypes of myeloid leukemia whose cells responded best to the treatment combinations reported here. The findings reported here, therefore, suggest that clinical trials of differentiation therapy of myeloid leukemia using the DCS combination are warranted.
